Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 12/20 | 0.52 |
| ▸ | CTSV | O60911 | 11/20 | 0.52 |
| ▸ | CTSS | P25774 | 11/20 | 0.52 |
| ▸ | CTSB | P07858 | 8/20 | 0.52 |
| ▸ | CTSK | P43235 | 8/20 | 0.52 |
| ▸ | PNMT | P11086 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | FPR2 | P25090 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16287362 | 1.00 | CTSL (0.52) | CTSLCTSVCTSSCTSBCTSK | |
| SCHEMBL31369749 | 1.00 | CTSL (0.52) | CTSLCTSVCTSSCTSBCTSK | |
| SCHEMBL29539732 | 1.00 | CTSL (0.52) | CTSLCTSVCTSSCTSBCTSK | |
| Hydrochloric Acid SCHEMBL16289133 | 0.98 | CTSL (0.51) | CTSLCTSVCTSSCTSBCTSK | |
| SCHEMBL14898396 | 0.88 | PNMT (0.51) | CTSLCTSVCTSSCTSBCTSK | |
| SCHEMBL14942915 | 0.88 | PNMT (0.51) | CTSLCTSVCTSSCTSBCTSK | |
| SCHEMBL21837394 | 0.85 | TAAR1 (0.51) | MAPK1FOLH1TAAR1 | |
| SCHEMBL21837393 | 0.85 | TAAR1 (0.51) | MAPK1FOLH1TAAR1 | |
| SCHEMBL23901512 | 0.85 | PNMT (0.53) | CTSLCTSVCTSSCTSBCTSK | |
| SCHEMBL11134765 | 0.85 | CTSL (0.50) | CTSLCTSVCTSSCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025100520-A1 | PEPTIDE, PEPTIDE COMPLEX, PHARMACEUTICAL COMPOSITION, COMPOSITION FOR CELL CULTURE, AND COMPOSITION FOR MEDICAL USE, DIAGNOSTIC USE, OR RESEARCH USE | ペプチドリーム株式会社 | 2025-05-15 | — | — | WO | claimed |
| US-12637494-B2 | Method for producing peptide containing non-natural amino acid | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-05-26 | — | — | US | disclosed |
| EP-4667483-A1 | HUMAN TRANSFERRIN RECEPTOR-BINDING PEPTIDE | JCR Pharmaceuticals Co., Ltd. (JP) | 2025-12-24 | — | — | EP | disclosed |
| US-20250361274-A1 | PEPTIDE AND PEPTIDE-CONTAINING AGENT | PEPTIDREAM INC. (JP) | 2025-11-27 | — | — | US | disclosed |
| EP-4628592-A1 | PEPTIDE PRODUCTION METHOD COMPRISING STEP FOR TRANSLATING AMINO ACID HAVING OXYGEN ATOM AT SPECIFIC POSITION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-10-08 | — | — | EP | disclosed |
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| US-12391971-B2 | Method for synthesizing peptides in cell-free translation system | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-08-19 | — | — | US | disclosed |
| EP-4570371-A2 | METHOD FOR PRODUCING CYCLIC ORGANIC COMPOUND | Chugai Seiyaku Kabushiki Kaisha (JP) | 2025-06-18 | — | — | EP | disclosed |
| WO-2025100520-A1 | PEPTIDE, PEPTIDE COMPLEX, PHARMACEUTICAL COMPOSITION, COMPOSITION FOR CELL CULTURE, AND COMPOSITION FOR MEDICAL USE, DIAGNOSTIC USE, OR RESEARCH USE | ペプチドリーム株式会社 | 2025-05-15 | — | — | WO | disclosed |
| EP-4541805-A1 | PEPTIDE AND PEPTIDE-CONTAINING AGENT | PeptiDream Inc. (JP) | 2025-04-23 | — | — | EP | disclosed |
| EP-2813512-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | Chugai Seiyaku Kabushiki Kaisha (JP) | 2014-12-17 | — | — | EP | disclosed |
| EP-2813512-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | Chugai Seiyaku Kabushiki Kaisha (JP) | 2014-12-17 | — | — | EP | disclosed |
| WO-2013100132-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | 中外製薬株式会社 (JP) | 2013-07-04 | — | — | WO | disclosed |
| US-20120071329-A1 | METHODS FOR IDENTIFYING COMPOUNDS OF INTEREST USING ENCODED LIBRARIES | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | US | disclosed |
| US-20090062147-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2009-03-05 | — | — | US | disclosed |
| US-7253198-B2 | Hydroxyethylamine derivatives for the treatment of Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-08-07 | — | — | US | disclosed |
| EP-1567488-B1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LTD (GB) | 2007-02-21 | — | — | EP | disclosed |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | US | disclosed |
| EP-1567488-A1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050619-A1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637494-B2 | Method for producing peptide containing non-natural amino acid | MRPL21, RPL21, RPL30 | CTSL 886/4885CTSV 1431/4885CTSS 1597/4885 |
| US-12391971-B2 | Method for synthesizing peptides in cell-free translation system | AARS1, NSUN3, RNGTT | CTSL 691/4885CTSV 848/4885CTSS 481/4885 |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | BACE2, PSEN2, BACE1 | CTSL 975/4885CTSV 457/4885CTSS 313/4885 |
| US-20250361274-A1 | PEPTIDE AND PEPTIDE-CONTAINING AGENT | BMP4, BMP1, BMPR2 | CTSL 1777/4885CTSV 3711/4885CTSS 3416/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | CTSL 120/4885CTSV 295/4885CTSS 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.